SCHEMBL24734359

SCHEMBL24734359

CCN(C(=O)OCc1ccccc1)[C@@H](Cc1ccc(C)cc1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.47
ALDH1A1 P00352 2/20 0.47
LMNA P02545 2/20 0.47
POLB P06746 1/20 0.47
HSD17B10 Q99714 1/20 0.47
P2RX7 Q99572 1/20 0.44
ITGB3 P05106 1/20 0.43
ITGA2B P08514 1/20 0.43
PPARG P37231 3/20 0.42
PPARA Q07869 3/20 0.42
ABCB1 P08183 2/20 0.42
MAPT P10636 1/20 0.41
ATM Q13315 1/20 0.41
CTSL P07711 1/20 0.41
CTSK P43235 1/20 0.41
CTRB1 P17538 2/20 0.40
TACR1 P25103 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MMP2 P08253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25179533 1.00 L3MBTL1 (0.47) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL7270975 0.94 ALDH1A1 (0.49) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL25182954 0.89 ADAMTS5 (0.47) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL30863429 0.87 SYK (0.41) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL29633716 0.87 SYK (0.41) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL25178720 0.86 PPARG (0.47) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL25183099 0.85 ITGB3 (0.57) L3MBTL1ALDH1A1LMNAP2RX7ITGB3
SCHEMBL22454757 0.82 PPARG (0.42) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL31072747 0.82 PPARG (0.42) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL25179041 0.82 PPARG (0.42) L3MBTL1ALDH1A1LMNAPOLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220411462-A1 METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-12-29 US disclosed
EP-4086272-A1 METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES Chugai Seiyaku Kabushiki Kaisha (JP) 2022-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411462-A1 METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES NGLY1, NPPA, VIP L3MBTL1 2234/4885ALDH1A1 4672/4885LMNA 3101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.